Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in Relapsed/Refractory NFE2L2 (NRF2)-Mutated and Wild-Type (WT) Squamous Non-Small Cell Lung Cancer (sqNSCLC)

NCT05275673 is registered in ClinicalTrials.gov with Faeth Therapeutics as lead sponsor.

NCT NCT05275673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05275673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in Relapsed/Refractory NFE2L2 (NRF2)-Mutated and Wild-Type (WT) Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Lead sponsor
Faeth Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
July 21, 2022
Completion date
January 24, 2023
Enrollment
7 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

nfe2l2 gene mutation, non-small cell lung cancer, squamous non-small cell neoplasm of lung, squamous non-small-cell lung cancer